Three-Dimensional Dose Model for the Comparison of 177Lu-HuCC49ΔCH2 and 177Lu-HuCC49 Radioimunotherapy in Mice Bearing Intraperitoneal Xenografts
dc.contributor.author | Roberson, Peter L. | en_US |
dc.contributor.author | Yokoyama, Shigeru | en_US |
dc.contributor.author | Rogers, Buck E. | en_US |
dc.contributor.author | Buchsbaum, Donald J. | en_US |
dc.date.accessioned | 2009-07-10T19:14:31Z | |
dc.date.available | 2009-07-10T19:14:31Z | |
dc.date.issued | 2003-04-01 | en_US |
dc.identifier.citation | Roberson, Peter L.; Yokoyama, Shigeru; Rogers, Buck E.; Buchsbaum, Donald J. (2003). "Three-Dimensional Dose Model for the Comparison of 177Lu-HuCC49ΔCH2 and 177Lu-HuCC49 Radioimunotherapy in Mice Bearing Intraperitoneal Xenografts." Cancer Biotherapy & Radiopharmaceuticals 18(2): 239-247 <http://hdl.handle.net/2027.42/63413> | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/63413 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12804050&dopt=citation | en_US |
dc.description.abstract | Uptake and dose distributions in peritoneal LS174T colon tumor xenografts were compared for a humanized construct of the CC49 (HuCC49) high-affinity anti-TAG-72 monoclonal antibody and a construct with the CH2 region deleted (HuCC49ΔCH2), both labeled with 177Lu using a PA-DOTA bifunctional chelating agent and injected in the peritoneum. Tumors were resected and serially sectioned at 1 h, 4 h, 24 h, and 48 h postinjection. Between 5 and 24 (average 16) sections were retained per tumor for autoradiography. The typical section interval was 340 μm and thickness was 16 μm. Tumor sections were air dried and placed on film and/or phosphor screen. Section images were digitized at 100 μm resolution electronically (phosphor screen) or by laser densitometer (film). Section images were used to generate tumor surface descriptions and activity distributions by reconstructing the activity densities in three dimensions. Three-dimensional dose-rate calculations, performed using a point kernel for 177Lu, were used to prepare radial histograms describing the variation in dose rate as a function of distance from the tumor center to surface. At early times postinjection, the 177Lu-HuCC49ΔCH2 antibody displayed higher dose rates near the tumor surface compared to the 177Lu-HuCC49 antibody. At 24 h postinjection, dose rate distributions appeared similar for both antibodies and more uniform than at earlier times. The 177Lu-HuCC49ΔCH2 antibody indicated improved uniformity at 48 h postinjection. Cell survival calculations based on the three-dimensional dose rate distributions favored 177Lu-HuCC49ΔCH2 for equal injection activities. However the most significant effect was the greater injected dose tolerated for the 177Lu-HuCC49ΔCH2 antibody based on equivalent estimated bone marrow dose. | en_US |
dc.format.extent | 330559 bytes | |
dc.format.extent | 2489 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Mary Ann Liebert, Inc., publishers | en_US |
dc.title | Three-Dimensional Dose Model for the Comparison of 177Lu-HuCC49ΔCH2 and 177Lu-HuCC49 Radioimunotherapy in Mice Bearing Intraperitoneal Xenografts | en_US |
dc.type | Article | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 12804050 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/63413/1/108497803765036418.pdf | |
dc.identifier.doi | doi:10.1089/108497803765036418 | en_US |
dc.identifier.source | Cancer Biotherapy & Radiopharmaceuticals | en_US |
dc.identifier.source | Cancer Biotherapy & Radiopharmaceuticals | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.